April 1, 2026 · Phase 2 readout
JSPR Phase 2 readout: a negative outcome, -8.7%
On April 1, 2026, Briquilimab — Jasper Therapeutics, Inc. (Chronic Spontaneous Urticaria) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -8.7% in the window around the event. It had already run -22.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$0.88
1d before
$0.80
Event day
$0.69
1d after
$0.68
5d after
Pre-catalyst setup
-22.2%
30-day run-up
6739%
30-day volatility
1.9×
volume spike